Updated just now · Live
Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
Eli Lilly and Company operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for LLY.
How to read insider trading filings
Johnson & Johnson
UnitedHealth Group Incorporated
AbbVie Inc.
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Abbott Laboratories
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). LLY Stock Intelligence Report. [stoxpulse.com/stocks/lly]
Disclaimer: The information on this page about Eli Lilly and Company (LLY) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Eli Lilly and Company.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Eli Lilly’s US$7b Kelonia Deal Reshapes Oncology A...
1h ago
How CVS And Amazon Chipped Away At Eli Lilly, Novo...
1h ago
StoxPulse AI results for LLY: Pulse Score 52.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$869.14B
P/E Ratio
46.8
EPS
$7.39
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Eli Lilly and Company discovers, develops, and markets pharmaceutical products worldwide. The company focuses on diabetes, oncology, immunology, and neuroscience, with leading products including Mounjaro, Verzenio, and Trulicity.
Eli Lilly’s US$7b Kelonia Deal Reshapes Oncology And Valuation Story
How CVS And Amazon Chipped Away At Eli Lilly, Novo Nordisk Stocks
Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front. How to invest early to grow your wealth
Did Amazon Just Wreck All of Hims & Hers Upside Potential?
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon.
Why Did Eli Lilly Stock Drop Today?
Which S&P500 stocks are gapping on Tuesday?